Liver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight

The liver cirrhosis market is expected to witness steady growth over the coming years, driven by the rising prevalence of chronic liver diseases, including hepatitis B, hepatitis C, alcohol-associated liver disease, and MASLD. In addition, a robust pipeline of novel therapies such as Efruxifermin (Akero Therapeutics), Belapectin (Galectin Therapeutics), PHIN-214 (PharmaIN), Volixibat (Mirum Pharmaceuticals), PVT201 (Parvus Therapeutics), PRI-724 (Prism Pharma), BI 3802876 (Boehringer Ingelheim), and others, is expected to transform the treatment landscape.

LAS VEGAS, Aug. 24, 2026 /PRNewswire/ — Recently published Liver Cirrhosis Market Insights report includes a comprehensive understanding of current treatment practices, liver cirrhosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Liver Cirrhosis Market Summary

• The total liver cirrhosis treatment market size is expected to grow positively by 2036 in the leading markets.
• The United States accounted for the largest liver cirrhosis treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• There are more than 3 million diagnosed prevalent cases of liver cirrhosis in 2025 across the 7MM.
• Leading liver cirrhosis companies, such as Akero Therapeutics, Galectin Therapeutics, PharmaIN, Mirum Pharmaceuticals, Parvus Therapeutics, Prism Pharma, Boehringer Ingelheim, and others, are developing new liver cirrhosis treatment drugs that can be available in the liver cirrhosis market in the coming years. 
• The promising liver cirrhosis therapies in clinical trials include Efruxifermin, Belapectin, PHIN-214, Volixibat, PVT201, PRI-724, BI 3802876, and others.

Discover liver cirrhosis clinical trial 2026 update press release @ https://www.delveinsight.com/report-store/liver-cirrhosis-market

Key Factors Driving the Growth of the Liver Cirrhosis Market 

• Rising Prevalence of Chronic Liver Diseases: The increasing incidence of chronic liver conditions such as hepatitis B, hepatitis C, alcohol-associated liver disease (ALD), and metabolic dysfunction-associated steatotic liver disease (MASLD) is driving the growing burden of liver cirrhosis. This expanding patient population continues to fuel demand for effective diagnostic tools and therapeutic interventions.
• Advancements in Diagnostic Technologies: The adoption of non-invasive diagnostic methods, including transient elastography, advanced imaging techniques, and blood-based biomarkers, has improved early detection and disease monitoring. Earlier diagnosis enables timely intervention, increasing the utilization of liver cirrhosis-related healthcare services.
• Improved Management of Cirrhosis Complications: Advances in the management of complications such as portal hypertension, ascites, hepatic encephalopathy, and variceal bleeding have improved patient survival and quality of life. Longer disease management periods contribute to sustained demand for therapies and supportive care.
• Emerging Disease-Modifying Therapies: The liver cirrhosis treatment landscape is evolving with the development of antifibrotic agents, regenerative therapies, stem cell-based approaches, and targeted biologics. A robust clinical pipeline is expected to introduce novel therapies such as Efruxifermin (Akero Therapeutics), Belapectin (Galectin Therapeutics), PHIN-214 (PharmaIN), Volixibat (Mirum Pharmaceuticals), and others, capable of slowing disease progression and improving patient outcomes.

Sharad Chandra Vinayak, Assistant Project Manager of Forecasting & Analytics at DelveInsight, said that the pharmaceutical companies are actively evaluating antifibrotic agents, anti-inflammatory therapies, regenerative medicines, and combination treatment strategies designed to target multiple pathogenic pathways simultaneously. In parallel, advances in precision medicine, biomarker-guided patient selection, and companion diagnostics are expected to enhance treatment efficacy while supporting more personalized approaches to care.

Liver Cirrhosis Market Analysis

• The rising burden of liver cirrhosis is driven by several contributing factors, including the increasing prevalence of obesity, diabetes, metabolic syndrome, excessive alcohol intake, chronic hepatitis B and C infections, an aging population, and improved survival among individuals with chronic liver disease.
• While there are currently no approved therapies capable of reversing liver cirrhosis, advances in clinical management have substantially improved patient outcomes. 
• Existing treatment approaches primarily focus on eliminating or controlling the underlying cause, slowing disease progression, preventing complications such as portal hypertension, ascites, and hepatic encephalopathy, and providing comprehensive supportive care. 
• Continued progress in antifibrotic and regenerative medicine is expected to further enhance long-term outcomes and potentially reduce the reliance on liver transplantation.
• Several investigational therapies, including antifibrotic, anti-inflammatory, and regenerative agents such as belapectin and efruxifermin, are currently being evaluated for the treatment of liver cirrhosis. 
• In addition, several promising candidates are progressing through different stages of clinical development, reflecting a robust pipeline that is anticipated to broaden future therapeutic options.
• The liver cirrhosis market is poised for significant evolution as innovative therapies targeting fibrosis, inflammation, metabolic dysfunction, and liver regeneration continue to advance through the clinical pipeline. 
• The anticipated launch of effective disease-modifying treatments has the potential to reshape the standard of care, improve clinical outcomes, and drive substantial market expansion at a strong CAGR over the forecast period.

Liver Cirrhosis Competitive Landscape

Some of the liver cirrhosis drugs under development include Efruxifermin (Akero Therapeutics), Belapectin (Galectin Therapeutics), PHIN-214 (PharmaIN), Volixibat (Mirum Pharmaceuticals), PVT201 (Parvus Therapeutics), PRI-724 (Prism Pharma), BI 3802876 (Boehringer Ingelheim), and others.

Efruxifermin (EFX), previously known as AKR-001, is Akero Therapeutics’ lead investigational candidate for the treatment of MASH cirrhosis. Designed for convenient once-weekly subcutaneous administration, EFX has demonstrated consistent and robust clinical activity, supporting its potential to become a best-in-class therapy if approved. The drug is currently being assessed in the Phase IIb SYMMETRY trial involving patients with biopsy-confirmed MASH and compensated F4 cirrhosis. Clinical findings to date suggest that EFX has the potential to provide meaningful therapeutic benefits for patients with MASH-related cirrhosis and remains in Phase II clinical development.

Galectin Therapeutics’ Belapectin (GR-MD-02) is an investigational complex carbohydrate therapy that inhibits galectin-3, a key protein implicated in the development of liver fibrosis and fatty liver disease. Galectin-3 is also involved in fibrotic processes affecting multiple organs, including the liver, lungs, kidneys, heart, and vascular system. By binding to galectin proteins and blocking their activity, belapectin aims to interrupt fibrosis progression. Preclinical studies have demonstrated its potential to reverse liver fibrosis and cirrhosis, highlighting its promise as a therapeutic candidate.

Pharma IN is advancing PHIN-214, an investigational vasopressor therapy for patients with advanced cirrhosis. PHIN-214 is a partial vasopressin V1a receptor agonist designed to lower portal hypertension while offering a broad therapeutic index that may improve both safety and efficacy compared with existing vasopressor treatments. Administered as a subcutaneous self-injection, the therapy is intended for use across a range of healthcare settings, enabling patients to manage advanced cirrhosis more conveniently and independently.

The anticipated launch of these emerging therapies are poised to transform the liver cirrhosis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the liver cirrhosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about the latest treatments for liver cirrhosis 2026 @ Liver Cirrhosis Therapeutics Drugs Market

Recent Developments in the Liver Cirrhosis Market

• In June 2026, Galectin Therapeutics Inc. announced that it received positive feedback during a recent in-person Type C meeting with the FDA, reinforcing the development of belapectin as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis (MASH)-related cirrhosis and portal hypertension.
• In November 2025, Akero Therapeutics, Inc. reported new data from the Phase 2b SYMMETRY and HARMONY trials evaluating efruxifermin in patients with compensated cirrhosis (F4c) associated with metabolic dysfunction-associated steatohepatitis (MASH) and pre-cirrhotic (F2–F3) MASH, respectively.

Liver Cirrhosis Epidemiology Segmentation

The liver cirrhosis epidemiology section provides insights into the historical and current liver cirrhosis patient pool and forecasted trends for the leading markets. The US showed the highest diagnosed prevalent population of liver cirrhosis compared to the other 7MM countries, with more than 2 million cases in 2025.

The liver cirrhosis treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Prevalent Cases of Liver Cirrhosis
• Total Diagnosed Prevalent Cases of Liver Cirrhosis 
• Gender-specific Diagnosed Prevalent Cases of Liver Cirrhosis 
• Age-specific Diagnosed Prevalent Cases of Liver Cirrhosis 
• Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis

Scope of the Liver Cirrhosis Market Report

• Liver Cirrhosis Patient Population Forecast
• Liver Cirrhosis Therapeutics Market Size
• Liver Cirrhosis Pipeline Analysis
• Liver Cirrhosis Market Size and Trends
• Liver Cirrhosis Market Opportunity
• Liver Cirrhosis Market Unmet Needs
• KOL’s Views on Liver Cirrhosis
• Liver Cirrhosis Market Access and Reimbursement

Download the report to understand the liver cirrhosis treatment market @ Liver Cirrhosis Injection

Table of Contents

Related Reports

Liver Cirrhosis Clinical Trial Analysis

Liver Cirrhosis Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key liver cirrhosis companies, including Versantis AG, Mirum Pharmaceuticals, Sagimet Biosciences, TenNor Therapeutics, Prism Pharma, Vedanta Biosciences, Lipocine, Gwo Xi Stem Cell Applied Technology, Galectin Therapeutics, Resolution Therapeutics, Ipsen, AstraZeneca, and others.

Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis Market

Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced hepatocellular carcinoma with CPB liver cirrhosis companies, including Bristol Myers Squibb (BMS), Merck & Co., Roche, Genentech, Bayer, AstraZeneca, Exelixis, Eli Lilly, Novartis, Gilead Sciences, and others.

Alcohol-associated Liver Disease Market

Alcohol-associated Liver Disease Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ALD companies, including Bausch Health, GSK, Alfasigma (Intercept Pharmaceuticals), Altimmune, Nterica, and others.

Metabolic Dysfunction-Associated Steatohepatitis Market

Metabolic Dysfunction-Associated Steatohepatitis Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MASH companies including Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Inc., Akero Therapeutics, Inc., 89bio, Inc., Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics Inc., Lipocine Inc., Viking Therapeutics, Inc., Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Inc., Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai) Co., Ltd., Hepion Pharmaceuticals, Inc., Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences Inc., Ionis Pharmaceuticals, Corcept Therapeutics, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/liver-cirrhosis-market-to-expand-significantly-through-2036-driven-by-emerging-therapies-and-increasing-disease-burden–delveinsight-302858052.html

SOURCE DelveInsight Business Research, LLP